Key clinical point: Circulating tumor DNA may be predictive of relapse in patients with early-stage primary breast cancer treated with curative intent.
Major finding: Detection of circulating tumor DNA was associated with a hazard ratio for relapse of 25.2 (P less than .001).
Study details: A validation study of samples from 101 patients with breast cancer, plus 43 additional patients from an earlier study for secondary analyses.
Disclosures: The study was funded by Breast Cancer Now, Le Cure, and National Institute for Health Research funding to the Biomedical Research Centre at the Royal Marsden Hospital and the Institute of Cancer Research. Dr. Garcia-Murillas reported no disclosures. Multiple coauthors reported grants and/or fees from various pharmaceutical companies.
Garcia-Murillias I et al. JAMA Oncol. 2019 Aug 1. doi: 10.1001/jamaoncol.2019.1838.